Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice

The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

Detalles Bibliográficos
Autores principales: Goel, Gaurav, Sun, Weijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517427/
https://www.ncbi.nlm.nih.gov/pubmed/26215324
http://dx.doi.org/10.1186/s13045-015-0183-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517427/
https://www.ncbi.nlm.nih.gov/pubmed/26215324
http://dx.doi.org/10.1186/s13045-015-0183-8

Ejemplares similares